STAT

JULY 26, 2023

They’re focused this summer on reining in pharmacy middlemen to make the system fairer — but none of their many proposals will actually tackle the core dynamic that has incentivized higher drug prices. There are major packages on so-called PBM reform percolating in at least six different congressional committees.

Drug Pricing 237

Drug Pricing Packaging Pharmaceutical Companies Pharmaceutical Companies 237

Pharmaceutical Technology

NOVEMBER 21, 2022

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).

Drug Pricing 69

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 69

Pharmaceutical Technology

NOVEMBER 21, 2022

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 52

Pharmaceutical Technology

FEBRUARY 7, 2023

An example is NICE’s Quality Adjusted Life Year score, used to price drugs in the UK. Some nations such as France base their decisions on the drug’s medical benefit and clinical added value versus existing therapies. Overall, it is never too soon to begin market access activities, but it can easily be too late.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Inpatient Drug Pricing Packaging 52

pharmaphorum

JANUARY 22, 2021

We don’t believe there will be draconian price cuts, for the same reason. The Biden administration could put additional scrutiny on drug prices, but more drastic measures, such as allowing Medicare to negotiate with pharma companies directly, are still unlikely.”.

Drug Pricing 63

Drug Pricing Packaging Biosimilars Pharmaceutical Companies 63